Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 1;2019(53):lgz007.
doi: 10.1093/jncimonographs/lgz007.

Oral Complications of Chronic Graft-Versus-Host Disease

Affiliations
Review

Oral Complications of Chronic Graft-Versus-Host Disease

Jane M Fall-Dickson et al. J Natl Cancer Inst Monogr. .

Abstract

The increasing clinical indications for hematopoietic stem cell transplantation (HSCT) and improved clinical care throughout and following HSCT have led to not only long-term survival but also to an increasing incidence and prevalence of graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) affects almost 50% of adult patients post-HSCT, with increasing incidence in pediatric patients as well. Oral cGVHD specifically has a reported prevalence ranging from 45% to 83% in patients who develop cGVHD and is more extensive in adult patients than in children. Oral cGVHD affects patients through clinically significant oral symptoms that may lead to significantly decreased caloric intake, oral infections, and increased health service utilization, and may thus affect overall health and survival. The most commonly used therapy for mucosal involvement of oral cGVHD is topical high-dose and ultra-high potency corticosteroids, and calcineurin inhibitors. This review of oral complications of cGVHD presents the clinical significance of oral cGVHD to HSCT survivors, our current understanding of the pathobiology of oral cGVHD and gaps in this evidence, and the global targeted interdisciplinary clinical research efforts, including the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Current challenges regarding the management of oral cGVHD and strategies to advance our scientific understanding of this clinically significant chronic oral disease are presented.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Erythema, lichen-like changes, and ulceration and pseudomembrane in adult patient with oral chronic graft-versus-host disease.
Figure 2.
Figure 2.
The National Institutes of Health oral chronic graft-versus-host disease clinical scoring instrument (form A, chronic graft-versus-host disease activity assessment-clinician report).
Figure 3.
Figure 3.
Pathobiology model of oral chronic graft-versus-host disease (Courtesy of Jacqueline W. Mays, DDS, MHSc, PhD, National Institute of Dental and Craniofacial Research, National Institutes of Health).

References

    1. Treister N, Schubert MS, Fall-Dickson JM.. Oral chronic graft vs host disease In: Vogelsang GB, Pavletic SZ, eds. Chronic Graft-Versus-Host Disease: Interdisciplinary Management. New York: Cambridge University; 2009:182–198.
    1. Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW.. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;194:327–346. - PMC - PubMed
    1. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ.. Transplantation’s greatest challenges: advances in chronic graft-versus-host-disease. Biol Blood Marrow Transplant. 2007;13(1 Suppl 1):2–10. - PubMed
    1. Zecca M, Prete A, Rondelli R.. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;1004:1192–1200. - PubMed
    1. Soto E, Fall-Dickson J, Berger A.. Oral manifestations and complications of cancer treatment In: Berger AM, Shuster JL, Von Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology. 4th ed.Philadelphia: Lippincott Williams & Wilkins; 2013:247–264.

Publication types

MeSH terms